Asthma and COPD Drug Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032

CHAPTER 1. Industry Overview of Asthma and COPD Drug Market

1.1. Definition and Scope

1.1.1. Definition of Asthma and COPD Drug

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Asthma and COPD Drug Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Asthma and COPD Drug Market By Indication

1.2.3. Asthma and COPD Drug Market By Drug Class

1.2.4. Asthma and COPD Drug Market By Region

CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Drug Class

2.2.1. Secondary Source

2.2.2. Primary Source

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Asthma and COPD Drug Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Asthma and COPD Drug Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Price Trend of Key Raw Materials

3.8.1. Raw Material Suppliers

3.8.2. Proportion of Manufacturing Cost Structure

3.8.2.1. Raw Material

3.8.2.2. Labor Cost

3.8.2.3. Manufacturing Expense

3.9. Regulatory Compliance

3.10. Competitive Landscape, 2022

3.10.1. Player Positioning Analysis

3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Manufacturing Plant Analysis

4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022

4.2. R&D Status of Major Manufacturers in 2022

CHAPTER 5. Asthma and COPD Drug Market By Indication

5.1. Introduction

5.2. Asthma and COPD Drug Revenue By Indication

5.2.1. Asthma and COPD Drug Revenue (USD Billion) and Forecast, By Indication, 2020-2032

5.2.2. Asthma

5.2.2.1. Asthma Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

5.2.3. Chronic Obstructive Pulmonary Disease (COPD)

5.2.3.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 6. Asthma and COPD Drug Market By Drug Class

6.1. Introduction

6.2. Asthma and COPD Drug Revenue By Drug Class

6.2.1. Asthma and COPD Drug Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032

6.2.2. Bronchodilators

6.2.2.1. Bronchodilators Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.2.2. Anticholinergic Agents

6.2.2.2.1. Anticholinergic Agents Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.2.3. Long-acting Beta-2 Agonists

6.2.2.3.1. Long-acting Beta-2 Agonists Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.2.4. Short-acting Beta-2 Agonists

6.2.2.4.1. Short-acting Beta-2 Agonists Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3. Anti-inflammatory Drugs

6.2.3.1. Anti-inflammatory Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.2. Phosphodiesterase Type-4 Inhibitors

6.2.3.2.1. Phosphodiesterase Type-4 Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.3. Anti-leukotrienes

6.2.3.3.1. Anti-leukotrienes Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.4. Oral and Inhaled Corticosteroids

6.2.3.4.1. Oral and Inhaled Corticosteroids Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.3.5. Other

6.2.3.5.1. Other Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.4. Monoclonal Antibodies

6.2.4.1. Monoclonal Antibodies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

6.2.5. Combination Drugs

6.2.5.1. Combination Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032

CHAPTER 7. North America Asthma and COPD Drug Market By Country 

7.1. North America Asthma and COPD Drug Market Overview

7.2. U.S.

7.2.1. U.S. Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

7.2.2. U.S. Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

7.3. Canada

7.3.1. Canada Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

7.3.2. Canada Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

7.4. North America PEST Analysis

CHAPTER 8. Europe Asthma and COPD Drug Market By Country

8.1. Europe Asthma and COPD Drug Market Overview

8.2. U.K.

8.2.1. U.K. Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

8.2.2. U.K. Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

8.3. Germany

8.3.1. Germany Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

8.3.2. Germany Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

8.4. France

8.4.1. France Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

8.4.2. France Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

8.5. Spain

8.5.1. Spain Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

8.5.2. Spain Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

8.6. Rest of Europe

8.6.1. Rest of Europe Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

8.6.2. Rest of Europe Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

8.7. Europe PEST Analysis

CHAPTER 9. Asia Pacific Asthma and COPD Drug Market By Country

9.1. Asia Pacific Asthma and COPD Drug Market Overview

9.2. China

9.2.1. China Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.2.2. China Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.3. Japan

9.3.1. Japan Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.3.2. Japan Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.4. India

9.4.1. India Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.4.2. India Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.5. Australia

9.5.1. Australia Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.5.2. Australia Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.6. South Korea

9.6.1. South Korea Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.6.2. South Korea Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.7. Rest of Asia-Pacific

9.7.1. Rest of Asia-Pacific Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

9.7.2. Rest of Asia-Pacific Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

9.8. Asia Pacific PEST Analysis

CHAPTER 10. Latin America Asthma and COPD Drug Market By Country

10.1. Latin America Asthma and COPD Drug Market Overview

10.2. Brazil

10.2.1. Brazil Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

10.2.2. Brazil Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

10.3. Mexico

10.3.1. Mexico Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

10.3.2. Mexico Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

10.4. Rest of Latin America

10.4.1. Rest of Latin America Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

10.4.2. Rest of Latin America Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

10.5. Latin America PEST Analysis

CHAPTER 11. Middle East & Africa Asthma and COPD Drug Market By Country 

11.1. Middle East & Africa Asthma and COPD Drug Market Overview

11.2. GCC

11.2.1. GCC Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

11.2.2. GCC Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

11.3. South Africa

11.3.1. South Africa Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

11.3.2. South Africa Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

11.4. Rest of Middle East & Africa

11.4.1. Rest of Middle East & Africa Asthma and COPD Drug Revenue (USD Billion) and Forecast By Indication, 2020-2032

11.4.2. Rest of Middle East & Africa Asthma and COPD Drug Revenue (USD Billion) and Forecast By Drug Class, 2020-2032

11.5. Middle East & Africa PEST Analysis

CHAPTER 12. Player Analysis Of Asthma and COPD Drug Market

12.1. Asthma and COPD Drug Market Company Share Analysis

12.2. Competition Matrix

12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment

12.2.2. New Product Launches and Product Enhancements

12.2.3. Mergers And Acquisition In Global Asthma and COPD Drug Market

12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 13. Company Profile

13.1. GlaxoSmithKline

13.1.1. Company Snapshot

13.1.2. Business Overview

13.1.3. Financial Overview

13.1.3.1. Revenue (USD Billion), 2022

13.1.3.2. GlaxoSmithKline 2022 Asthma and COPD Drug Business Regional Distribution

13.1.4. Product /Service and Specification

13.1.5. Recent Developments & Business Strategy

13.2. AstraZeneca

13.3. Boehringer Ingelheim

13.4. Novartis

13.5. Teva Pharmaceutical Industries

13.6. Sanofi

13.7. Roche

13.8. Merck & Co.

13.9. Pfizer

13.10. Johnson & Johnson

13.11. Abbott Laboratories

13.12. Sunovion Pharmaceuticals Inc.